PARIS--(BUSINESS WIRE)--Biocitech Life Sciences Park, France - Cellectis S.A. (Alternext: ALCLS), the genome engineering company for therapeutic, life science research and other biotechnology industries, announced today the achievement of a key milestone set at the time of its 2007 IPO. The company also provides an update on its objectives and timeline.
